Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06899074 · ClinicalTrials.gov registry record · NA

Omega-3 Supplementation for Pediatric Migraine

A NA study of Migraine, sponsored by University of North Carolina, Chapel Hill.

Active
Registry status
NA
Development phase
58
Enrollment target
1
Study location

NCT06899074 is a NA study of Migraine that is active but no longer recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 58 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06899074, a NA study of Migraine, is active but no longer recruiting, sponsored by University of North Carolina, Chapel Hill.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to assess the biochemical and clinical effects of omega-3 polyunsaturated fatty acid (PUFA) supplementation in youth suffering from migraine, including its effects on migraine disability, psychological distress, and overall quality of life. This study duration 12 weeks.

Conditions Studied

Interventions

  • OTHER Matching Placebo
  • DIETARY_SUPPLEMENT Omega 3 Polyunsaturated Fats

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2025-04-17
Est. Completion 2026-03
Phase NA

What the Registry Record Tells You About NCT06899074

The ClinicalTrials.gov registry entry for NCT06899074 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (84% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.

NCT06899074 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06899074 about?

NCT06899074 is a clinical study titled "Omega-3 Supplementation for Pediatric Migraine". The purpose of the study is to assess the biochemical and clinical effects of omega-3 polyunsaturated fatty acid (PUFA) supplementation in youth suffering from migraine, including its effects on migraine disability, psychological distress, and overall quality of life. This study duration 12 weeks.

What is the current status of trial NCT06899074?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 58 participants. The study started on 2025-04-17. Estimated completion is 2026-03.

What conditions does trial NCT06899074 study?

This clinical trial studies the following conditions: Migraine.

What interventions are being tested in trial NCT06899074?

The interventions under investigation include: Matching Placebo (OTHER), Omega 3 Polyunsaturated Fats (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06899074?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06899074 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.